Dynamics in Post-pandemic Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry: Supply and Demand, Markets and Prices 2021-2027
Table of Contents
1 Product Introduction and Overview
- 1.1 Product Definition
- 1.2 Product Specification
- 1.3 Global Market Overview
- 1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Forecast (2016-2027)
- 1.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value CAGR by Region
- 1.4 Market Drivers, Inhibitors
- 1.4.1 Market Drivers
- 1.4.2 Market Inhibitors
- 1.4.3 COVID-19 Impact Analysis
2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Supply by Company
- 2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Company
- 2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Company
- 2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Company
- 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Location and Sales Area of Main Manufacturers
- 2.5 Trend of Concentration Rate
3 Global and Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Category
- 3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Category Introduction
- 3.1.1 Eluxadoline
- 3.1.2 Alosetron
- 3.1.3 Rifaximin
- 3.1.4 Loperamide
- 3.1.5 Diphenoxylate + Atropine
- 3.1.6 Dicyclomine and Hyoscyamine
- 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Category
- 3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Category (2016-2021)
- 3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Category (2016-2021)
- 3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Category (2016-2021)
- 3.3 North America: by Category
- 3.4 Europe: by Category
- 3.5 Asia Pacific: by Category
- 3.6 Central & South America: by Category
- 3.7 Middle East & Africa: by Category
4 Global and Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by End User/Segment
- 4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by End User/Segment
- 4.1.1 Hospitals
- 4.1.2 Clinics
- 4.1.3 Others
- 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by End User/Segment
- 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by End User/Segment (2016-2021)
- 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by End User/Segment (2016-2021)
- 4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by End User/Segment (2016-2021)
- 4.3 North America: by End User/Segment
- 4.4 Europe: by End User/Segment
- 4.5 Asia Pacific: by End User/Segment
- 4.6 Central & South America: by End User/Segment
- 4.7 Middle East & Africa: by End User/Segment
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Region
- 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Region
- 5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Region
- 5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region
- 5.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 5.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 5.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 5.5 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 5.6 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
6 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
- 6.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
- 6.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
- 6.2 United States
- 6.3 Canada
- 6.4 Mexico
7 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
- 7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
- 7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
- 7.2 Germany
- 7.3 France
- 7.4 UK
- 7.5 Italy
- 7.6 Russia
- 7.7 Spain
8 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 8.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
- 8.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
- 8.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
- 8.2 China
- 8.3 Japan
- 8.4 Korea
- 8.5 Southeast Asia
- 8.6 India
- 8.7 Australasia
9 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 9.1 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
- 9.1.1 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
- 9.1.2 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
- 9.2 Brazil
- 9.3 Argentina
- 9.4 Colombia
10 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
- 10.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
- 10.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
- 10.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
- 10.2 Iran
- 10.3 Israel
- 10.4 Turkey
- 10.5 South Africa
- 10.8 Saudi Arabia
11 Supply Chain and Manufacturing Cost Analysis
- 11.1 Supply Chain Analysis
- 11.2 Production Process Chart Analysis
- 11.3 Raw Materials and Key Suppliers Analysis
- 11.3.1 Raw Materials Introduction
- 11.3.2 Raw Materials Key Suppliers List
- 11.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
- 11.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channel and Distributors Analysis
- 11.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channel
- 11.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
- 11.6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Downstream Major Buyers
12 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Category and by End User/Segment
- 12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume and Sales Value Forecast (2022-2027)
- 12.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Category
- 12.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Forecast by Category
- 12.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Forecast by Category
- 12.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Category
- 12.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by End User/Segment
- 12.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Forecast by End User/Segment
- 12.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Forecast by End User/Segment
- 12.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by End User/Segment
13 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Region/Country
- 13.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Region (2022-2027)
- 13.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Forecast by Region (2022-2027)
- 13.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Forecast by Region (2022-2027)
- 13.2 North America Market Forecast
- 13.3 Europe Market Forecast
- 13.4 Asia Pacific Market Forecast
- 13.5 Central & South America Market Forecast
- 13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
- 14.1 Salix Pharmaceuticals Ltd
- 14.1.1 Company Information
- 14.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
- 14.1.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
- 14.1.4 SWOT Analysis
- 14.2 Pfizer
- 14.2.1 Company Information
- 14.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
- 14.2.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
- 14.2.4 SWOT Analysis
- 14.3 GlaxoSmithKline
- 14.3.1 Company Information
- 14.3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
- 14.3.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
- 14.3.4 SWOT Analysis
- 14.4 AstraZenenca
- 14.4.1 Company Information
- 14.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
- 14.4.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
- 14.4.4 SWOT Analysis
- 14.5 Astellas Pharmaceuticals
- 14.5.1 Company Information
- 14.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
- 14.5.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
- 14.5.4 SWOT Analysis
- 14.6 Actavis
- 14.6.1 Company Information
- 14.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
- 14.6.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
- 14.6.4 SWOT Analysis
...
15 Conclusion
16 Methodology
Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.
Segmented by Category
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Segmented by End User/Segment
Hospitals
Clinics
Others
Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia
Key manufacturers included in this survey
Salix Pharmaceuticals Ltd
Pfizer
GlaxoSmithKline
AstraZenenca
Astellas Pharmaceuticals
Actavis